What is the PROTECT Survey?

This online survey is running across Europe and seeks to uncover who may benefit from the innovation that is long acting injectable PrEP. The European Commission (EC) has authorised Apretude (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention. The availability of cabotegravir LA for PrEP will differ from country to country across the EU. It is important for health services and policy makers to understand who may be interested in taking long acting injectable PrEP so that resources can be most effectively allocated. The PROTECT survey is for people from the following groups:

  • Men who have sex with men
  • Trans* people
  • Heterosexual people
  • People living with HIV

Learn more about the background to the PROTECT Survey

The survey takes less 15 to 20 minutes to complete, depending on your characteristics. It is anonymous and you can withdraw at anytime. It is important that we hear from a wide variety of people across Europe about their experiences and preferences. HIV can affect anyone and the nature of the epidemic has been changing in recent years. Men who have sex with men continue to be a group that is heavily impacted by the virus but so are people with a transgender experience and increasingly also heterosexual people.


Conference News

The PROTECT team is presenting analysis of PROTECT survey data at the 25th International AIDS Conference in Munich. The following in person poster presentations will be given:

The PROTECT Survey Team

Our multidisciplinary team comes from around the world and works from Maastricht, a cross-roads between the Netherlands, Germany and Belgium. We have experience with creating and analysing similar large online surveys such as EMIS (The European Men who have sex with Men Internet Survey) and have expertise in HIV prevention and Lesbian, Gay, Bisexual, Transgender, Intersex, Queer (LGBTIQ) health.